Shares of Metropolis Healthcare surged nearly 7% on Q4 business updates. As of 9:30 am the shares were trading 6.07% higher at ₹1,910.00 on NSE.
Metropolis Healthcare stated that its core business revenue (excluding revenue from COVID-19, COVID-19 allied tests, and PPP contracts) jumped approximately 15% year-over-year (YoY) in Q4 of FY24.
During the period under review, the company’s revenue growth in the core business was largely driven by an 8% volume growth.
The healthcare service provider reported a 7% increase in revenue per patient (RPP) growth for Q4 FY24, which was largely driven by growth in the specialty tests segment, premium wellness segment, and price increases.
The company’s B2C revenues jumped 18% YoY in Q4FY24. Investments made in expanding the network, acquiring talent, upgrading information technology, and refining processes are proving fruitful, as shown by the rise in sales volumes across both the B2C and B2B sectors.
EBIDTA Margins for Q4FY24 showed a consistent upward trend both quarter-over-quarter and year-over-year. This boost in margin can be attributed mainly to the surge in volumes and implemented price increases.
During the current quarter, the company has repaid its debt, resulting in a debt-free status as of 31 March 2024.
